Revelation Biosciences (NASDAQ:REVB) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Revelation Biosciences (NASDAQ:REVB) from a hold rating to a sell rating in a report published on Thursday morning.

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB opened at $2.59 on Thursday. The firm has a fifty day moving average price of $2.97 and a two-hundred day moving average price of $5.66. Revelation Biosciences has a one year low of $2.36 and a one year high of $60.80. The company has a market cap of $2.34 million, a price-to-earnings ratio of -0.01 and a beta of 0.19.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($2.11) EPS for the quarter, beating the consensus estimate of ($6.88) by $4.77. Equities research analysts expect that Revelation Biosciences will post -49.33 EPS for the current fiscal year.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.